Evidence map›Paper›PMID 27320318›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Hui Jiang, Xueying Mao, Xiaoyi Huang, Jing Zhao, Lumei Wang, Jingjing Xu, Hongwei Zhang, Yongjie Lu, Yongwei Yu

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Prevalence and clinical application ofAsian journal of andrology
    Pooled it
  3. Deep Sequencing Reveals Novel Mutations inInternational journal of molecular sciences · 2025
    Article
  4. Article
  5. TMPRSS2: Potential Biomarker for COVID-19 Outcomes.Journal of clinical pharmacology · 2020
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Hui JiangDepartment of Pathology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Xueying MaoMolecular Oncology & Imaging Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Xiaoyi HuangDepartment of Pathology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Jing ZhaoDepartment of Pathology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Lumei WangChanghai Hospital, Second Military Medical University, Shanghai, 200433, China.
Jingjing XuDepartment of Pathology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Hongwei ZhangDepartment of Epidemiology, Second Military Medical University, Shanghai, 200433, China.
Yongjie LuChanghai Hospital, Second Military Medical University, Shanghai, 200433, China.
Yongwei YuDepartment of Pathology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China. yongweiyu@126.com.
Second Military Medical University · CNChanghai Hospital · CNQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the commonest male malignancy in the Western world, but its morbidity is much lower in China. The principal aim of this study was to evaluate the frequency of TMPRSS2:ERG fusion in Chinese prostate cancer patients using immunohistochemistry and reverse transcription polymerase chain (RT-PCR). In addition, we compared the ERG protein expression with TMPRSS2:ERG fusion gene. The relationship between ERG expression and clinicopathologic features was also examined. Samples from patients who underwent radical prostatectomies in Changhai Hospital (Shanghai, China) were collected and stored in ethically approved tissue banks. One hundred seventy-four prostate cancer tissue samples and 10 normal tissues were marked on standard hematoxylin-eosin (HE) sections, punched out of the paraffin blocks and inserted into a recipient block using tissue arrayer instruments. Immunohistochemistry and RT-PCR were employed to detect TMPRSS2:ERG fusion gene. ERG was highly expressed in the nuclei of endothelial cells of vessels and weak cytoplasmic staining was occasionally observed. ERG positive staining was present in 14.9 % (26/174) of the tumor samples in microarray. All benign prostate samples were found to be negative. RT-PCR results revealed that 11.1 % (15/135) were TMPRSS2:ERG fusion positive. Altogether, there was a good agreement of ERG immunostaining with the presence of TMPRSS2:ERG. However, no correlation was observed between ERG expression and age, Gleason score, stage, surgical margin, and seminal vesicle involvement in Chinese patients. In the present study, we identified a high correlation between ERG expression and ERG TMPRSS2:ERG, with 100 % sensitivity and 88.9 % specificity. The expression level of ERG was unrelated to the age, Gleason score, stage, surgical margin, and seminal vesicle involvement. Therefore, the association between ERG expression and prostate cancer based on Chinese population should be further investigated in the future.

Indexed as

Gene Expression Regulation, NeoplasticAgedAsian PeopleCell NucleusChinaHumansImmunohistochemistryMaleMiddle AgedNeoplasm GradingNeoplasm StagingOncogene Proteins, FusionProstateProstatectomyProstatic NeoplasmsReverse Transcriptase Polymerase Chain ReactionERG protein, humanOncogene Proteins, FusionSerine EndopeptidasesTMPRSS2-ERG fusion protein, humanTMPRSS2 protein, humanTranscriptional Regulator ERGChineseDiagnosisImmunohistochemistryProstate cancerTMPRSS2:ERG

Identifiers

PMID27320318
OpenAlexW2432143519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.